Further, disruption of the Rb-Raf-1 interaction using an eight-amino-acid peptide [69] or a small molecule disruptor [71] inhibited the growth of NSCLC tumors in xenograft models, suggesting that disrupting the Rb-Raf-1 interaction might be a viable strategy to combat NSCLC, especially those harboring K-Ras mutations [72, 73]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.